Accessing your own genomic data is a civil right but requires strategies to manage safety

January 4, 2018, Cell Press
Credit: CC0 Public Domain

The Genetic Information Nondiscrimination Act of 2008, or GINA, expanded individuals' access to genetic information by forcing changes to the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule. These amendments, finalized in 2013 and 2014, gave Americans a civil right to obtain copies of their own genetic test results stored at HIPAA-regulated laboratories. In a commentary published January 4 in the American Journal of Human Genetics, Barbara J. Evans, Alumnae College Professor of Law and Professor of Electrical and Computer Engineering at the University of Houston, describes how civil rights and safety concerns collided after these changes and offers strategies to reconcile the two.

GINA celebrates its tenth anniversary this year amid ongoing controversy, says Evans. "Scholars poke fun at GINA for 'solving' a problem that, as far as the evidence shows, never actually existed: genetic discrimination in employment and health insurance," she says. "Meanwhile, GINA declined to tackle problems that cause real headaches for people who are about to undergo genetic testing, such as whether the results might make it impossible to buy long-term care insurance."

The individual access right GINA created is also a source of heated controversy. Lawmakers foresaw that Americans need a right of access, for example, to protect themselves from being wrongly linked to a crime based on a genetic test mix-up or to help them assess how much hackers stole from a research lab that was storing their genomic data. But GINA created that right by amending the HIPAA Privacy Rule, which left some loose ends.

"You only have an access right if the party that stores your data happens to be HIPAA-regulated. Most direct-to-consumer testing and cloud data storage services are not HIPAA-regulated, so you may not have an access right if your data are there, says Evans. Also, the new access right was not successfully integrated with other regulations. "You have one regulator telling research labs to provide access, to protect . Other regulators try to block access, citing safety concerns. Labs are caught in the middle and many Americans are being deprived of a federally protected civil right to see their data."

The source of the dispute is that many research laboratories are HIPAA regulated and subject to the new access right. Giving people access to data from research laboratories is controversial because the genomic data they produce do not always contain clinically relevant information (only about 200 gene sequences have known clinical significance). Someone could misinterpret the data to pursue needless medical treatment or waste healthcare resources to clarify findings that they misunderstand.

Because of concerns that research data could be misused, bioethicists and medical professionals, as well as safety regulators like the U.S. Food and Drug Administration (FDA) and the Centers for Medicare and Medicaid Services, which regulates clinical labs, at times, have taken stances that cause research labs to block people's new access right. "The good news is that we aren't forced to choose between having safety or having civil rights," Evans adds, "We can have both, but it requires regulators to be smart and think outside their usual boxes."

In her commentary, Evans says that safety regulators have many tools to address safety risks without blocking access, such as requiring warnings and disclosures and sending informational letters to physicians. She also recommends publishing reliability scores for organizations that provide genomic interpretation services. Congress may also need to authorize funds to help research laboratories deal with the cost of providing access after research grants end.

"Having access to your own genomic data also lets you exercise important constitutional rights, such as your First Amendment rights to assemble and petition the government. You can go on social media and assemble groups of people with genes like yours and lobby Congress to spend more research dollars studying how those genes affect your health," says Evans. "Like the right to vote, to one's own is a foundational civil right that empowers people to protect all their other civil rights."

Explore further: Navigating the ethical clash between access to health information and proprietary databases

More information: American Journal of Human Genetics, Evans BJ.: "HIPAA's individual right of access to genomic data: reconciling safety and civil rights" http://www.cell.com/ajhg/fulltext/S0002-9297(17)30493-7 , DOI: 10.1016/j.ajhg.2017.12.004

Related Stories

Navigating the ethical clash between access to health information and proprietary databases

May 15, 2017
Sharing medical information, including genomic data, has the potential to benefit public health. However, companies that generate that information have a legal right to protect it as a trade secret. Legal and ethical conflict ...

Patients can now get test results straight from the lab: HHS

February 3, 2014
(HealthDay)—Patients may now get their medical test results directly from the laboratory, without having to go through a doctor's office, the U.S. Department of Health and Human Services announced Monday.

ASHG opposes revised EEOC regulations weakening genetic privacy

May 16, 2016
The American Society of Human Genetics (ASHG) opposes the U.S. Equal Employment Opportunity Commission's (EEOC) newly revised Regulations under the Americans with Disabilities Act (ADA) and under the Genetic Information Nondiscrimination ...

Final HIPAA omnibus rule goes into effect March 26

February 9, 2013
(HealthDay)—The final omnibus rule, which makes changes to the Health Insurance Portability and Accountability Act (HIPAA) of 1996, goes into effect March 26, and physicians must be in compliance by Sept. 23.

Genomic data sharing is critical to improving genetic health care

January 5, 2017
There are an estimated 5,000 - 7,000 rare genetic diseases, each of which can vary dramatically and be caused by a multitude of different genetic changes. Even common diseases with genetic influences may also have rare variants ...

Congressional action needed to optimize regulation of genomic tests

May 27, 2015
The latest generation of genomic testing offers a chance for significant improvements in patient care, disease prevention, and possibly even the cost-effectiveness of healthcare. A new report recommends that Congress act ...

Recommended for you

New platform poised to be next generation of genetic medicines

July 16, 2018
A City of Hope scientist has discovered a gene-editing technology that could efficiently and accurately correct the genetic defects that underlie certain diseases, positioning the new tool as the basis for the next generation ...

Overcoming a major barrier to developing liquid biopsies

July 16, 2018
The idea of testing blood or urine to find markers that help diagnose or treat disease holds great promise. But as technology has improved to allow researchers to examine tiny fragments of RNA, one major problem has led to ...

Genetic marker for drug risk in multiple sclerosis offers path toward precision medicine

July 16, 2018
A team of researchers has uncovered a specific gene variant associated with an adverse drug reaction resulting in liver injury in a people with multiple sclerosis (MS). It is the first time researchers have been able to establish ...

Researchers suggest new treatment for rare inherited cancers

July 16, 2018
Studying two rare inherited cancer syndromes, Yale Cancer Center (YCC) scientists have found the cancers are driven by a breakdown in how cells repair their DNA. The discovery, published today in Nature Genetics, suggests ...

AI accurately predicts effects of genetic mutations in biological dark matter

July 16, 2018
A new machine learning framework, dubbed ExPecto, can predict the effects of genetic mutations in the so-called "dark matter" regions of the human genome. ExPecto pinpoints how specific mutations can disrupt the way genes ...

Scientists sharpen the edges of cancer chemotherapy with CRISPR

July 13, 2018
Tackling unsolved problems is a cornerstone of scientific research, propelled by the power and promise of new technologies. Indeed, one of the shiniest tools in the biomedical toolkit these days is the genome editing system ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.